Compare
Amgen vs Vir Biotechnology (AMGN vs VIR)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Vir Biotechnology (VIR) +126.1%; so far this year the figures are +40.7% and +102.5%.
Amgen is the larger company by market value, about 119.2 times the size of Vir Biotechnology.
Revenue grew +8.2% at AMGN and +1696.0% at VIR over the last year.
AMGN yields 2.16%. VIR pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | VIR | |
|---|---|---|
| Price | $460.42 | $12.21 |
| 1-day | +0.03% | +10.80% |
| YTD | +40.67% | +102.49% |
| 1 year | +43.94% | +126.11% |
| 3 years | +76.51% | +56.74% |
| Market cap | $249.1B | $2.1B |
| P/E | 26.7 | — |
| P/S | 6.40 | 6.91 |
| P/B | 17.35 | 2.33 |
| Revenue growth | +8.20% | +1696.00% |
| EPS growth | +33.30% | — |
| Gross margin % | 70.9 | 22.6 |
| Net margin % | 24.1 | -61.0 |
| ROE % | 65.4 | -20.6 |
| Debt / equity | 3.76 | 0.00 |
| FCF yield % | 3.8 | -6.8 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 1.74 |
| RSI (14) | 60.5 | 59.9 |
| Technical rating |